Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease

Montserrat Serra-Batiste1, James Tolchard1,2, Fabrice Giusti3

  • 1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute Science and Technology (BIST), Barcelona, Spain.

Insights

Researchers stabilized a pore-forming amyloid-beta oligomer (βPFO) using amphipols, enabling its study in Alzheimer's disease research. This method maintains the oligomer's structure under dilution, crucial for further biological validation.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Neuroscience

Background:

  • A beta-sheet pore-forming amyloid-beta 42 oligomer (βPFO) has been prepared, exhibiting a stable β-barrel structure.
  • βPFO's relevance to Alzheimer's disease (AD) requires its stabilization in aqueous solutions for biological testing.
  • Current stabilization in dodecyl phosphocholine (DPC) micelles is lost upon dilution, hindering further research.

Purpose of the Study:

  • To develop a method for transferring βPFO from DPC micelles to a stable, biomimetic membrane environment.
  • To validate the structural integrity of βPFO when stabilized by alternative agents under dilution conditions.
  • To enable future in vivo studies of βPFO's role in Alzheimer's disease pathogenesis.

Main Methods:

  • Exchange of DPC micelles with amphipols (APols), amphipathic polymers designed for membrane protein stabilization.
  • Testing of three distinct APol types to identify optimal stabilization conditions for the βPFO/DPC complex.
  • Characterization of the resulting βPFO/APol complex using biochemical and structural biology techniques.

Main Results:

  • Non-ionic APols (NAPols) were found to effectively trap the βPFO/DPC complex.
  • The βPFO oligomer structure was maintained in the βPFO/NAPol complex even under high dilution.
  • Structural integrity was confirmed through biochemical assays and advanced structural biology methods.

Conclusions:

  • Successful transfer and stabilization of βPFO from DPC micelles to NAPols has been achieved.
  • This stabilization method preserves the oligomer's structure under dilution, overcoming a major limitation.
  • This work represents a critical first step towards the in vivo validation of βPFO in Alzheimer's disease.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...